Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Viola

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Endocrinology and Metabolism|January 1, 2019
Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent CasesRossella Elisei, Antonio Matrone, Laura Valerio, et al.
The Journal of Clinical Endocrinology and Metabolism|June 30, 2012
Modifications in the papillary thyroid cancer gene profile over the last 15 yearsCristina Romei, Laura Fugazzola, Efisio Puxeddu, et al.
European Journal of Endocrinology|July 21, 2020
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSHMaria Cristina Campopiano, Debora Podestà, Francesca Bianchi, et al.
Journal of Medical Genetics|July 30, 2016
New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double <i>RET</i> mutationsCristina Romei, Francesca Casella, Alessia Tacito, et al.
Genes|September 13, 2019
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET MutationsRossella Elisei, Alessia Tacito, Teresa Ramone, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 2012
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort studyRossella Elisei, David Viola, Liborio Torregrossa, et al.
Clinical Endocrinology|December 3, 2014
Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?Cristina Romei, Alessia Tacito, Eleonora Molinaro, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 20, 2021
Role of Prophylactic Central Compartment Lymph Node Dissection on the Outcome Of Patients With Papillary Thyroid Carcinoma and Synchronous Ipsilateral Cervical Lymph Node MetastasesLuigi De Napoli, Antonio Matrone, Karin Favilla, et al.
Oncology Letters|May 29, 2018
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experienceCristina Romei, Alessia Tacito, Eleonora Molinaro, et al.
The Journal of Clinical Endocrinology and Metabolism|October 26, 2019
Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian CenterEleonora Molinaro, Maria Cristina Campopiano, Letizia Pieruzzi, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Endocrinology and Metabolism|January 1, 2019
Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent CasesRossella Elisei, Antonio Matrone, Laura Valerio, et al.
The Journal of Clinical Endocrinology and Metabolism|June 30, 2012
Modifications in the papillary thyroid cancer gene profile over the last 15 yearsCristina Romei, Laura Fugazzola, Efisio Puxeddu, et al.
European Journal of Endocrinology|July 21, 2020
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSHMaria Cristina Campopiano, Debora Podestà, Francesca Bianchi, et al.
Journal of Medical Genetics|July 30, 2016
New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double <i>RET</i> mutationsCristina Romei, Francesca Casella, Alessia Tacito, et al.
Genes|September 13, 2019
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET MutationsRossella Elisei, Alessia Tacito, Teresa Ramone, et al.
The Journal of Clinical Endocrinology and Metabolism|October 16, 2012
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort studyRossella Elisei, David Viola, Liborio Torregrossa, et al.
Clinical Endocrinology|December 3, 2014
Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?Cristina Romei, Alessia Tacito, Eleonora Molinaro, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 20, 2021
Role of Prophylactic Central Compartment Lymph Node Dissection on the Outcome Of Patients With Papillary Thyroid Carcinoma and Synchronous Ipsilateral Cervical Lymph Node MetastasesLuigi De Napoli, Antonio Matrone, Karin Favilla, et al.
Oncology Letters|May 29, 2018
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experienceCristina Romei, Alessia Tacito, Eleonora Molinaro, et al.
The Journal of Clinical Endocrinology and Metabolism|October 26, 2019
Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian CenterEleonora Molinaro, Maria Cristina Campopiano, Letizia Pieruzzi, et al.
Pageof 6